Myeloma Cancer Trials

54767414SMM3001

54767414SMM3001 – A phase III randomized, multicenter study of subcutaneous daratumumab versus active monitoring in subjects with high-risk smoldering multiple myeloma.

1. What type of cancer? What stage?
   1. Smoldering multiple myeloma.
2. Who is eligible?
   1. Diagnosed within 5 years.
3. How will I be treated?
   1. Daratumumab – an antibody-based drug, directed against CD38.

For physicians: more information about this specific trial at clinicaltrials.gov.